Short answer
Fulcrum Therapeutics, Inc. (FULC) filed an 8-K current report with the SEC on June 11, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). $370,040 retention payment for CEO Alex Sapir following restructuring and pociredir discontinuation.
Fulcrum Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- $370,040 retention payment for CEO Alex Sapir following restructuring and pociredir discontinuation
- $195,480 for Chief Legal Officer Curtis Oltmans and $195,200 for CFO Alan Musso
- Payments contingent on Change in Control or qualifying termination after transitional duties
- Vice President-level employees receive expanded Change in Control protections, increasing potential transaction-related obligations
- Principal accounting officer Greg Tourangeau departing by mutual agreement without financial-reporting disagreement disclosed
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Fulcrum Therapeutics, Inc. 8-K filings
Get the next FULC 8-K as it lands
Follow FULC for push alerts, or ask the research agent what this filing means.